Positive versus negative sentinel nodes in early breast cancer patients: Axillary or loco-regional relapse and survival. A study spanning 2000-2012

Breast

Volumn 22, Issue 5, 2013, Pages 902-907

  Garcia Fernandez A ^a,b   Chabrera, C ^c,d   Garcia Font M ^e   Fraile, M ^a   Lain, J M ^f   Barco, I ^a   Gonzalez C ^a   Gonzalez S ^a   Rene A ^a   Veloso, E ^a   Cassado J ^a   Pessarrodona, A ^a   Gimenez N ^a,g  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT CATALÀ DE LA SALUT   (Spain)

^c School of Health Science TecnoCampus Mataró Maresme   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^f Hospital of Terrassa   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Breast neoplasms; Mortality; Neoplasm recurrence; Sentinel lymph node biopsy; Survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE FREE INTERVAL; DISTANT METASTASIS; EARLY CANCER; FOLLOW UP; HUMAN; LOCAL METASTASIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MICROMETASTASIS; MORTALITY; PRIORITY JOURNAL; SENTINEL LYMPH NODE METASTASIS;

BREAST NEOPLASMS; MORTALITY; NEOPLASM RECURRENCE; SENTINEL LYMPH NODE BIOPSY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AXILLA; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

EID: 84884168225     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.015     Document Type: Article

References (34)

1. Fisher E.R., Costantino J., Fisher B., Redmond C. Pathologic findings from theNational Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer 1993, 71:2141-2150.
2. Singletary S.E., Allred C., Ashley P., Bassett L.W., Berry D., Bland K., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. JClin Oncol 2002, 20:3628-3636.
3. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
4. Warmuth M.A., Bowen G., Prosnitz L.R., Chu L., Broadwater G., Peterson B., et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 1998, 83:1362-1368.
5. Hack T.F., Cohen L., Katz J., Robson L.S., Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. JClin Oncol 1999, 17:143-149.
6. Schrenk P., Rieger R., Shamiyeh A., Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000, 88:608-614.
7. Goyal A., Newcombe R.G., Chhabra A., Mansel R.E. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND. Ann Surg Oncol 2008, 15:262-267.
8. Kootstra J.J., Hoekstra-Weebers J.E., Rietman J.S., de Vries J., Baas P.C., Geertzen J.H., et al. Alongitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection. Ann Surg Oncol 2010, 17:2384-2394.
9. McMasters K.M., Wong S.L., Chao C., Woo C., Tuttle T.M., Noyes R.D., et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 2001, 234:292-300.
10. Jakub J.W., Cox C.E., Pippas A.W., Gardner M., Pendas S., Reintgen D.S. Controversial topics in breast lymphatic mapping. Semin Oncol 2004, 31:324-332.
11. Krang D.N., Harlow S. Current status of sentinel node surgery in breast cancer. Oncology 2003, 17:1663-1676.
12. Collins C.D. The sentinel node in breast cancer. Cancer Imaging 2008, 8(_):S10-S18.
13. Kothari M.S., Rusby J.E., Agusti A.A., MacNeill F.A. Sentinel lymph node biopsy after previous axillary surgery: a review. Eur J Surg Oncol 2012, 38:8-15.
14. Smidt M.L., Janssen C.M., Kuster D.M., Bruggink E.D., Strobbe L.J. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005, 12:29-33.
15. Madsen A.H., Jensen A.R., Christiansen P., Garne J.P., Cold S., Ewertz M., et al. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group. Acta Oncol 2008, 47:239-247.
16. Krag D., Weaver D., Ashikaga T., Moffat F., Klimberg V.S., Shriver C., et al. The sentinel node in breast cancer a multicenter validation study. NEngl J Med 1998, 339:941-946.
17. Fraile M., Rull M., Julián F.J., Fusté F., Barnadas A., Llatjós M., et al. Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol 2000, 11:701-705.
18. Mansel R.E., Fallowfield L., Kissin M., Goyal A., Newcombe R.G., Dixon J.M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. JNatl Cancer Inst 2006, 98:599-609.
19. Veronesi U., Paganelli G., Viale G., Luini A., Zurrida S., Galimberti V., et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006, 7:983-990.
20. Zavagno G., De Salvo G.L., Scalco G., Bozza F., Barutta L., Del Bianco P., et al. Arandomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008, 247:207-213.
21. García Fernández A., Fraile M., Giménez N., Reñe A., Torras M., Canales L., et al. Use of axillary ultrasound, ultrasound-fine needle aspiration biopsy and magnetic resonance imaging in the preoperative triage of breast cancer patients considered for sentinel node biopsy. Ultrasound Med Biol 2011, 37:16-22.
22. Mariscal Martínez A., Solà M., de Tudela A.P., Julián J.F., Fraile M., Vizcaya S., et al. Radioguided localization of nonpalpable breast cancer lesions: randomized comparison with wire localization in patients undergoing conservative surgery and sentinel node biopsy. AJR Am J Roentgenol 2009, 193:1001-1009.
23. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
24. Collins L.C., Marotti J.D., Gelber S., Cole K., Ruddy K., Kereakoglow S., et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012, 131:1061-1066.
25. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. NEngl J Med 2009, 360:790-800.
26. Hunt K.K., Ballman K.V., McCall L.M., Boughey J.C., Mittendorf E.A., Cox C.E., et al. Factors associated with local-regional recurrence after a negative sentinel node dissection results of the ACOSOG Z0010 trial. Ann Surg 2012, 256:428-436.
27. van Wely B.J., van den Wildenberg F.J., Gobardhan P., van Dalen T., Borel Rinkes I.H., Theunissen E.B., et al. Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients. Eur J Surg Oncol 2012, 38:925-931.
28. Gobardhan P.D., Elias S.G., Madsen E.V., van Wely B., van den Wildenberg F., Theunissen E.B., et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study. Ann Surg Oncol 2011, 18:1657-1664.
29. van Wely B.J., Teerenstra S., Schinagl D.A., Aufenacker T.J., de Wilt J.H., Strobbe L.J. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Br J Surg 2011, 98:326-333.
30. van Wely B.J., Smidt M.L., de Kievit I.M., Wauters C.A., Strobbe L.J. False-negative sentinel lymph node biopsy. Br J Surg 2008, 95:1352-1355.
31. García Fernández A., Giménez N., Fraile M., González S., Chabrera C., Torras M., et al. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010. Breast 2012, 21:366-373.
32. Tada K., Ogiya A., Kimura K., Morizono H., Iijima K., Miyagi Y., et al. Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer. World J Surg Oncol 2010, 8:6.
33. Postma E.L., van Wieringen S., Hobbelink M.G., Verkooijen H.M., van den Bongard H.J., Borel Rinkes I.H., et al. Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat 2012, 134:735-741.
34. Bourre J.C., Payan R., Collomb D., Gallazzini-Crepin C., Calizzano A., Desruet M.D., et al. Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation?. Eur J Nucl Med Mol Imaging 2009, 36:758-764.